Home › Why Gilead Is Still A Growth Stock - Focus On HIV And China, With Projections For 2016
 

Keywords :   


Why Gilead Is Still A Growth Stock - Focus On HIV And China, With Projections For 2016

2015-12-08 14:07:47| Biotech - Topix.net

Yet it continues to demonstrate growing earnings power from medical trends in HIV, new products in HIV and HCV, and geographic expansion. At its current valuation, I believe that Gilead Sciences is reasonably valued even if its non-HCV, non-HIV pipeline flops.

Tags: for with china stock

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Hurricane Leslie Graphics
06.10Hurricane Leslie Forecast Discussion Number 16
06.10Hurricane Leslie Wind Speed Probabilities Number 16
06.10Hurricane Leslie Forecast Advisory Number 16
06.10Hurricane Leslie Public Advisory Number 16
06.10Summary for Hurricane Leslie (AT3/AL132024)
06.10Hurricane Kirk Graphics
06.10Tropical Storm Milton Graphics
More »